Deal Overview: SK Capital Partners is nearing a deal to acquire Swixx Biopharma SA, a Swiss pharmaceutical distributor, for approximately €1.5 billion ($1.8 billion), with an announcement expected soon.
Competitive Landscape: SK Capital has outbid other potential buyers, including DKSH Holding AG and Lone Star, to secure the acquisition of Swixx, which specializes in commercializing medicines in diverse markets.
Company Profile: Swixx, owned by HBM Healthcare Investments and its management, operates in 45 countries and generated over €900 million in revenue in 2024, focusing on regulatory and packaging requirements for pharmaceuticals.
Investment Focus: SK Capital, founded in 2007, manages around $10 billion in assets and invests primarily in life sciences, specialty chemicals, and materials, although the finalization of the Swixx deal remains uncertain.
Wall Street analysts forecast IXJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IXJ is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast IXJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IXJ is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 99.790
Low
Averages
High
Current: 99.790
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
